Validation of LOH profiles for assessing oral cancer risk.
This perspective examines the report by Zhang and colleagues in this issue of the journal (beginning on page 1081) on the validation and refinement of a set of risk markers for oral premalignant lesion progression that incorporates loss of heterozygosity markers. The perspective also discusses some of the challenges and opportunities of incorporating predictive biomarkers into monitoring and refined enrollment criteria for prevention studies.
Department of Pathology, The University of Chicago, 5841 South Maryland Ave, MC 6101, Chicago, IL 60637, USA. Mark.Lingen@uchospitals.edu
Mark W
MW
Lingen
Eva
E
Szabo
D005260:Female; D006801:Humans; D019656:Loss of Heterozygosity / Q000235:genetics*; D008297:Male; D009062:Mouth Neoplasms / Q000235:genetics* / Q000473:pathology*; D011230:Precancerous Conditions / Q000235:genetics* / Q000473:pathology*